immutep (asx:imm) reports positive discussions with the fda and strong survival data
Published 1 year ago • 67 plays • Length 6:03Download video MP4
Download video MP3
Similar videos
-
8:42
immutep (asx:imm) announces positive results in head and neck cancer treatment
-
3:33
immutep (asx:imm) reports positive trial data
-
46:43
immutep (asx:bla) - tacti-003 positive data in patients with negative pd-l1 expression (cohort b)
-
15:49
immutep (asx:imm) - webinar presentation
-
5:10
immutep (asx:imm) reports first subject dosed in autoimmune disease study
-
5:10
immutep (asx:imm, nasdaq:immp) reports first subject dosed in autoimmune disease study
-
12:02
there's a multiple re-rate to be had in small caps. here's a way to take advantage of it
-
8:42
immutep (asx:imm) announces positive results in head and neck cancer treatment
-
47:53
immutep (asx:imm) tacti-003 results, june 2024
-
16:06
immutep (asx:imm) - webinar presentation
-
16:07
immutep (asx:imm) - webinar presentation
-
5:42
immutep (asx:imm) receives fast track designation from fda
-
52:08
immutep (asx:imm) - update on tacti-002 phase ii and insight-003 phase 1 data presented at sitc 2022
-
31:08
immutep (asx:imm) 2023 agm - ceo presentation
-
0:21
immutep (asx:imm) receives positive feedback from fda
-
50:22
immutep (asx:imm) esmo congress results webinar, october 2023
-
7:17
immutep (asx:imm) delivering strong data in first-line non-small cell lung cancer
-
0:42
“the buzz” show: immutep limited (nasdaq: immp) rise on positive breast cancer data
-
4:44
immutep (asx:imm) - innovative cancer therapies
-
1:12:16
webinar:the last quarter of 2024 - ask me anything with fsmone research team
-
7:09
immutep (asx:imm) reports 71.4% response rate for lung cancer therapy